A high-level panel hosted by India discusses the issues of trade deals that inhibit access to medicines and also limit policy space for governments to legislate in public interest.
The Ministry of Commerce must be cautious of Free Trade Agreements being negotiated with the European Union as well as the Regional Comprehensive Economic Partnership that further strengthen or extend intellectual property (IP) monopolies.
Of the RCEP negotiating countries, it is India, rather than China, that has been the most outspoken in opposing US-style trade rules.
The letter says that this dispute over the compulsory license could prejudice resources for a new initiative called "Paz Colombia", as well as the US FTA with Colombia, and access to the TPP.
Access to affordable medicines could be severely restricted for millions of people around the world under the current proposals in the Regional Comprehensive Economic Partnership (RCEP) trade agreement?
Signing the TPP has provoked a debate on whether, when it comes into force, there will be a potential spike in medicines prices.
The historic decision to break barriers to improve access to costly medicines was taken during the “First Extraordinary Meeting of the Ministers of the Common Market of the South (Mercosur).
One element of TTIP has been largely ignored – the deal’s impact on developing countries.
India has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western drugmakers.
Revision of the legal framework on intellectual property is recommended to ensure compliance with the EU – Viet Nam Free Trade Agreement.
It’s no joke. The consequence that the Transpacific Treaty on Economic Cooperation (the English acronym for which is the TPP) recently signed by 12 countries in the Pacific Ocean, including Mexico, Peru and Chile on this side of the Pond, has on access to medicines is brutal.
"The battle to prevent this trade agreement from being implemented is far from over", asserts the humanitarian organization, joining the rejection that the treaty Chile signed in New Zealand arouses.
One immediate obstacle to getting the Trans-Pacific Partnership through US Congress lives in Jan Kemper’s laboratory an hour’s drive from the White House.
Deal’s fate rests on ‘talks about talks’ between senior officials as EU demands greater flexibility on imports.
As reported in Indian media, senior officials from the European Commission and India are expected to meet today in Brussels to hold talks on resuming negotiations on the proposed European Union-India free trade agreement.
Months after it called off talks between chief negotiators of the two sides on free trade agreement (FTA) to protest against the ban on sale of around 700 pharma products of a domestic company, India will meet officials from the European Union (EU) later next month to “take stock of the negotiations” on the long-pending FTA.
The escalation in patent protections is set to occur just as drug prices hit all-time highs in Canada and pharmaceutical investment in research and development sinks to decade-long lows.
Although TPP seems a remote issue, it could have a direct impact on EU consumers.
While the agreement was being negotiated, the US Trade Representative stated that a much-criticized arbitration process included in the TPP would not apply to intellectual property. Turns out, it does apply to IP.
A massive trade pact between 12 Pacific rim countries could limit the availability of affordable medicines, the head of the World Health Organization said